Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen Presents Data From Three Trials Evaluating BLINCYTO® (blinatumomab) In Acute Lymphoblastic Leukemia At ASH 2015

[PR Newswire] – THOUSAND OAKS, Calif., Dec. 7, 2015 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that new data from three Phase 2 trials support the efficacy and safety of BLINCYTO ® (blinatumomab) in . . . → Read More: Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen Presents Data From Three Trials Evaluating BLINCYTO® (blinatumomab) In Acute Lymphoblastic Leukemia At ASH 2015 Similar Articles: Company Update (NASDAQ:AMGN): European Commission Approves Amgen’s BLINCYTO® (blinatumomab) for the Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen to Present IMLYGIC™ (Talimogene Laherparepvec) Data at the 2015 International Congress of the Society for Melanoma Research Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Positive BLINCYTO® (blinatumomab) Phase 2 Study Results In Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia